Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Cash from Operations: 2020-2025

Historic Cash from Operations for Janux Therapeutics (JANX) over the last 5 years, with Sep 2025 value amounting to -$12.9 million.

  • Janux Therapeutics' Cash from Operations fell 476.24% to -$12.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$70.4 million, marking a year-over-year decrease of 90.37%. This contributed to the annual value of -$43.8 million for FY2024, which is 13.37% up from last year.
  • Per Janux Therapeutics' latest filing, its Cash from Operations stood at -$12.9 million for Q3 2025, which was up 46.01% from -$23.8 million recorded in Q2 2025.
  • In the past 5 years, Janux Therapeutics' Cash from Operations registered a high of $5.6 million during Q1 2021, and its lowest value of -$23.8 million during Q2 2025.
  • Its 3-year average for Cash from Operations is -$13.5 million, with a median of -$13.9 million in 2023.
  • Its Cash from Operations has fluctuated over the past 5 years, first tumbled by 543.40% in 2021, then soared by 80.95% in 2024.
  • Quarterly analysis of 5 years shows Janux Therapeutics' Cash from Operations stood at -$10.5 million in 2021, then fell by 13.66% to -$11.9 million in 2022, then grew by 16.89% to -$9.9 million in 2023, then slumped by 68.92% to -$16.7 million in 2024, then tumbled by 476.24% to -$12.9 million in 2025.
  • Its Cash from Operations stands at -$12.9 million for Q3 2025, versus -$23.8 million for Q2 2025 and -$17.0 million for Q1 2025.